Fragasso Group Inc. Sells 808 Shares of Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Apr 3rd, 2023

Fragasso Group Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 2.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,094 shares of the biopharmaceutical company’s stock after selling 808 shares during the period. Fragasso Group Inc.’s holdings in Pfizer were worth $2,054,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Lam Group Inc. bought a new position in Pfizer during the 4th quarter valued at about $25,000. Karp Capital Management Corp bought a new position in shares of Pfizer in the third quarter worth about $27,000. Worth Asset Management LLC bought a new position in shares of Pfizer in the first quarter worth about $29,000. My Personal CFO LLC bought a new position in shares of Pfizer in the fourth quarter worth about $32,000. Finally, Delos Wealth Advisors LLC raised its stake in shares of Pfizer by 100.0% in the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 400 shares during the last quarter. 67.62% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $40.80 on Monday. The company has a current ratio of 1.22, a quick ratio of 1.00 and a debt-to-equity ratio of 0.34. The firm’s fifty day moving average price is $41.98 and its two-hundred day moving average price is $45.61. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The firm has a market capitalization of $230.29 billion, a P/E ratio of 7.45, a price-to-earnings-growth ratio of 1.37 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. During the same period in the previous year, the company earned $1.08 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 3.3 EPS for the current year.

Insider Buying and Selling at Pfizer

In related news, major shareholder Pfizer Inc acquired 1,811,594 shares of the firm’s stock in a transaction on Friday, March 17th. The shares were purchased at an average cost of $2.76 per share, for a total transaction of $4,999,999.44. Following the completion of the acquisition, the insider now directly owns 5,952,263 shares in the company, valued at $16,428,245.88. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PFE. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price target for the company in a research report on Tuesday, February 7th. BMO Capital Markets decreased their price objective on shares of Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, February 1st. UBS Group set a $45.00 price objective on shares of Pfizer in a report on Tuesday, March 14th. Wells Fargo & Company reduced their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday, March 17th. Finally, Berenberg Bank set a $40.00 price target on shares of Pfizer in a report on Tuesday, February 7th. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $50.38.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.